Genvor Inc (OTC: GNVR)

Genvor Incorporated was incorporated in Florida on September 26, 2018, as “Allure Worldwide, Inc.,” and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from “Allure Worldwide, Inc.” to “Genvor Incorporated.” The Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the “Purchase Agreement”) with Genvor Inc., a Delaware corporation (“Old Genvor”) to acquire (the “Acquisition”) Old Genvor. On March 2, 2022, the Company and Old Genvor entered into a merger agreement (the “Merger Agreement”) to consummate the Acquisition, and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation (“Merger Subsidiary”), merged (the “Merger”) with and into Old Genvor, with each share of Old Genvor common stock issued immediately prior to the time of the merger automatically converted into the right to receive one share of common stock of the Company. On May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Old Genvor, each share of Old Genvor was exchanged for the right to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Old Genvor’s pre-merger shareholders (the “Merger Shares”), constituting a change of control of the Company, and Old Genvor became a wholly owned subsidiary of the Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the Acquisition, and subsequently the Company’s original founding shareholders cancelled 18,144,112 shares of Company common stock in connection with the Acquisition. Business Overview and Strategic Direction As a result of the Acquisition, the Company’s business plan is to continue the research, development, and future commercialization of sustainable crop protection and plant health solutions through its wholly owned subsidiary, Genvor. Genvor leverages a proprietary and growing library of patented peptides to address critical challenges in global agriculture. These peptides, which include antimicrobial peptides (AMPs) and nutritionally enhanced peptides (NEPs), are being developed to support plant defense against a wide spectrum of threats, including pathogens (fungi, bacteria, and viruses), toxins, and pest-related crop damage. In addition to direct disease resistance, Genvor’s peptide technologies show promising potential in other vital areas of crop protection and productivity. These include improved nutrient uptake efficiency, plant vigor, and stress tolerance, as well as insect control through naturally derived, targeted bioactive mechanisms. These multifunctional properties of peptides may lead to reductions in chemical pesticide usage and enhanced yield outcomes, contributing to more sustainable and economically viable farming systems. The company believes these technologies, once commercialized, may provide material benefits to growers globally by mitigating losses from plant disease and environmental stress, thereby supporting increased yields and improved food security in regions facing agricultural constraints. Beyond plant health, Genvor is also evaluating cross-sector applications of its peptide portfolio in animal health. Early research and collaboration opportunities are exploring the use of nutritionally enhanced peptides (NEPs) to improve feed efficiency, gut health, and overall performance in livestock and aquaculture systems. These applications align with global efforts to enhance protein production efficiency across the food chain, reduce reliance on antibiotics, and improve sustainability in animal agriculture. The Company’s strategic vision includes both internal development and external partnerships to accelerate the validation, regulatory approval, and commercialization of its core peptide technologies across plant and animal sectors. Genvor’s integrated approach to biological innovation places it at the intersection of agricultural productivity, environmental stewardship, and food system resilience.

Genvor generates revenue primarily through licensing and royalty opportunities from its peptide technologies. The Company does not expect revenue until the end of 2025, through the licensing and distribution of either or both the topical spray and seed trait, utilizing licensing and royalty opportunities. Genvor’s business model is to remain capital-light, focused on leveraging its third-party research and development through its initial CRADA with the USDA, and any subsequent CRADAs that may be granted, while also adopting a licensing approach to reduce “cash burn” or the need for significant manufacturing and marketing overhead. Genvor is highly scalable and capital efficient with minimal overhead relative to peers, allowing the Company to focus on core research and development competency.

The company operates through the following segments:

• Plant Health Solutions: Genvor develops anti-microbial peptides (AMPs) for direct disease resistance in plants against pathogens such as fungi, bacteria, and viruses, as well as for improved nutrient uptake efficiency, plant vigor, and stress tolerance. These peptides are being developed for two primary agricultural applications: as a non-chemical transgenic seed trait, whereby crops are engineered to express specific AMPs internally, and as a topical or foliar biological spray application (“bio-pesticide”) that can be used in integrated pest and disease management strategies.

• Animal Health and Nutrition: Genvor is researching and validating nutritionally enhanced peptides (NEPs) to improve feed efficiency, gut health, and overall performance in livestock and aquaculture systems. These peptides are designed to increase the protein content and feed density of common animal feedstocks such as corn and sweet potato, supporting performance improvements across poultry, swine, and aquaculture production systems and potentially reducing feed conversion ratios.

Genvor operates in the sustainable crop protection and plant health industry, positioning itself at the forefront of biological innovation in agriculture. The Company competes with established players such as Vestaron Corporation, BASF SE, Syngenta Crop Protection, Micropep Technologies, and Hello Nature, which offer peptide-derived insecticides, peptide-enhanced crop protection products, fungus-targeted peptide discovery pipelines, micropeptide solutions, and plant-stimulating peptides, respectively. Genvor’s competitive advantage lies in its proprietary library of patented peptides, its USDA Cooperative Research and Development Agreement (CRADA) that provides access to advanced laboratories and regulatory expertise, and its multifunctional peptide technologies that address multiple agricultural challenges simultaneously, including disease resistance, nutrient optimization, and stress tolerance, while reducing reliance on chemical pesticides.

Genvor serves growers globally across conventional and organic farming operations, with a focus on major row crops such as corn, soybeans, and cotton for its seed trait and topical spray applications. The Company also targets livestock and aquaculture producers for its nutritionally enhanced peptide applications in animal feed, aiming to improve feed efficiency and nutrient density in poultry, swine, and aquaculture systems. No specific customer names are disclosed in the filing.